...
首页> 外文期刊>Spine >Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft.
【24h】

Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft.

机译:与recombinant骨骨移植相比,使用重组人骨形态发生蛋白2 /抗压基质进行单级器械后外侧融合2年的临床结果和融合成功。

获取原文
获取原文并翻译 | 示例
           

摘要

STUDY DESIGN: This is a prospective, randomized study comparing iliac crest bone graft to bone morphogenetic protein (BMP)/compression resistant matrix in instrumented posterolateral fusions for single-level lumbar degenerative disease. A higher recombinant human bone morphogenetic protein (rhBMP)-2 dose and a carrier specific for posterior spine applications were used. OBJECTIVES: As part of a Food and Drug Administration IDE study, clinical outcomes and fusion rates of single-level instrumented posterolateral fusions using iliac crest bone graft or BMP/compression resistant matrix were evaluated. SUMMARY OF BACKGROUND DATA: Although iliac crest graft is the gold standard for lumbar fusion, alternatives to obviate the morbidity of graft harvest have become available. Randomized clinical trials have demonstrated equivalent fusion rates and clinical outcomes with rhBMP-2 and a collagen sponge versus autograft in anterior lumbar fusions. A human pilot study using rhBMP-2 with biphasic calcium phosphate demonstrated similar results for posterolateral fusions. METHODS: Demographic and perioperative data, Short Form 36, Oswestry Low Back Pain Disability Index, and leg and back pain scores were determined before surgery, and 1.5, 3, 6, 12, and 24 months after surgery. Independent neuroradiologists' evaluation of fine-cut computerized tomography scans with reconstructions were obtained at 6, 12, and 24 months. RESULTS: There were 98 subjects, 45 in the iliac crest bone graft group and 53 in the BMP/compression resistant matrix group. There were no significant differences for age, weight, sex, smoking, or previous surgery between the groups. The average operative time (2.9 hours) and blood loss (465 cc) in the iliac crest bone graft group was greater than in the BMP/compression resistant matrix group (2.4 hours and 273 cc). There were no significant differences in any outcome measure at all time intervals. The fusion rate was lower in the iliac crest bone graft group (73%) than in the BMP/compression resistant matrix group (88%) at P = 0.051. CONCLUSION: There was significant improvement of Short Form 36 (physical component score and pain), Oswestry Low Back Pain Disability Index, and leg and back pain scores in both groups over all time intervals. Surgical time and blood loss were significantly less in the BMP/compression resistant matrix group. The fusion rate in the BMP/compression resistant matrix group was significantly higher than the iliac crest bone graft group.
机译:研究设计:这是一项前瞻性,随机研究,比较instrument骨后植骨与单侧腰椎退行性疾病经器械后外侧融合的骨形态发生蛋白(BMP)/抗压基质。使用了更高剂量的重组人骨形态发生蛋白(rhBMP)-2剂量和后脊柱应用特异的载体。目的:作为美国食品药品监督管理局(FDA)研究的一部分,评估了使用using骨植骨或抗BMP /抗压基质的单级器械后外侧融合器的临床疗效和融合率。背景资料概述:尽管骨移植是腰椎融合术的金标准,但也有许多替代方法可以消除移植物的发病。随机临床试验已证明,rhBMP-2和胶原海绵与前路腰椎融合术相比自体移植具有相同的融合率和临床效果。一项使用rhBMP-2和双相磷酸钙的人类试验研究表明,后外侧融合的结果相似。方法:在手术前以及手术后1.5、3、6、12和24个月测定人口统计学和围手术期数据,简短表格36,Oswestry下腰痛残疾指数以及腿和背痛评分。在重建的第6、12和24个月时,独立的神经放射科医生对精细的计算机X线断层扫描进行了评估。结果:共有98名受试者,45骨植骨组45名,BMP /抗压基质组53名。两组之间的年龄,体重,性别,吸烟或以前的手术均无显着差异。骨植骨组的平均手术时间(2.9小时)和失血量(465 cc)大于BMP /抗压基质组的平均手术时间(2.4 h和273 cc)。在所有时间间隔内,任何结局指标均无显着差异。在P = 0.051时,in骨植骨组的融合率(73%)低于BMP /抗压基质组的融合率(88%)。结论:在所有时间间隔内,两组的短式36(身体成分评分和疼痛),Oswestry下腰痛残疾指数以及腿痛和背痛评分均得到显着改善。 BMP /抗压基质组的手术时间和失血量明显减少。 BMP /抗压基质组的融合率显着高于the骨移植组。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号